United States Oligonucleotide Therapeutics Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Oligonucleotide Therapeutics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Oligonucleotide Therapeutics Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Oligonucleotide Therapeutics Overall Market Size
2.1 United States Oligonucleotide Therapeutics Market Size: 2021 VS 2027
2.2 United States Oligonucleotide Therapeutics Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oligonucleotide Therapeutics Players in United States Market
3.2 Top United States Oligonucleotide Therapeutics Companies Ranked by Revenue
3.3 United States Oligonucleotide Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Oligonucleotide Therapeutics Companies in United States Market, by Revenue in 2020
3.5 Companies Oligonucleotide Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide Therapeutics Players in United States Market
3.6.1 List of Tier 1 Oligonucleotide Therapeutics Companies in United States
3.6.2 List of Tier 2 and Tier 3 Oligonucleotide Therapeutics Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Oligonucleotide Therapeutics Market Size Markets, 2021 & 2027
4.1.2 Antisense Oligonucleotide
4.1.3 Aptamer
4.1.4 Other
4.2 By Type - United States Oligonucleotide Therapeutics Revenue & Forecasts
4.2.1 By Type - United States Oligonucleotide Therapeutics Revenue, 2016-2021
4.2.2 By Type - United States Oligonucleotide Therapeutics Revenue, 2022-2027
4.2.3 By Type - United States Oligonucleotide Therapeutics Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Oligonucleotide Therapeutics Market Size, 2021 & 2027
5.1.2 Neuromuscular Diseases
5.1.3 ATTR
5.1.4 Hepatic VOD
5.1.5 Other
5.2 By Application - United States Oligonucleotide Therapeutics Revenue & Forecasts
5.2.1 By Application - United States Oligonucleotide Therapeutics Revenue, 2016-2021
5.2.2 By Application - United States Oligonucleotide Therapeutics Revenue, 2022-2027
5.2.3 By Application - United States Oligonucleotide Therapeutics Revenue Market Share, 2016-2027
6 Oligonucleotide Therapeutics Companies Profiles
6.1 Biogen
6.1.1 Biogen Company Details
6.1.2 Biogen Business Overview
6.1.3 Biogen Oligonucleotide Therapeutics Introduction
6.1.4 Biogen Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.1.5 Biogen Recent Developments
6.2 Sarepta Therapeutics
6.2.1 Sarepta Therapeutics Company Details
6.2.2 Sarepta Therapeutics Business Overview
6.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction
6.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.2.5 Sarepta Therapeutics Recent Developments
6.3 Jazz Pharmaceuticals
6.3.1 Jazz Pharmaceuticals Company Details
6.3.2 Jazz Pharmaceuticals Business Overview
6.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction
6.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.3.5 Jazz Pharmaceuticals Recent Developments
6.4 Bausch & Lomb
6.4.1 Bausch & Lomb Company Details
6.4.2 Bausch & Lomb Business Overview
6.4.3 Bausch & Lomb Oligonucleotide Therapeutics Introduction
6.4.4 Bausch & Lomb Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.4.5 Bausch & Lomb Recent Developments
6.5 Alnylam Pharmaceuticals
6.5.1 Alnylam Pharmaceuticals Company Details
6.5.2 Alnylam Pharmaceuticals Business Overview
6.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Introduction
6.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.5.5 Alnylam Pharmaceuticals Recent Developments
6.6 Dynavax Technologies
6.6.1 Dynavax Technologies Company Details
6.6.2 Dynavax Technologies Business Overview
6.6.3 Dynavax Technologies Oligonucleotide Therapeutics Introduction
6.6.4 Dynavax Technologies Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.6.5 Dynavax Technologies Recent Developments
6.7 Kastle therapeutics
6.7.1 Kastle therapeutics Company Details
6.7.2 Kastle therapeutics Business Overview
6.7.3 Kastle therapeutics Oligonucleotide Therapeutics Introduction
6.7.4 Kastle therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.7.5 Kastle therapeutics Recent Developments
6.8 Akcea Therapeutics
6.8.1 Akcea Therapeutics Company Details
6.8.2 Akcea Therapeutics Business Overview
6.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Introduction
6.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021)
6.8.5 Akcea Therapeutics Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. Oligonucleotide Therapeutics Market Opportunities & Trends in United States Market
Table 2. Oligonucleotide Therapeutics Market Drivers in United States Market
Table 3. Oligonucleotide Therapeutics Market Restraints in United States Market
Table 4. Key Players of Oligonucleotide Therapeutics in United States Market
Table 5. Top Oligonucleotide Therapeutics Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Oligonucleotide Therapeutics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Oligonucleotide Therapeutics Revenue Share by Companies, 2016-2021
Table 8. Companies Oligonucleotide Therapeutics Product Type
Table 9. List of Tier 1 Oligonucleotide Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Oligonucleotide Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - United States Oligonucleotide Therapeutics Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Oligonucleotide Therapeutics Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Oligonucleotide Therapeutics Revenue (US$, Mn), 2022-2027
Table 14. By Application - United States Oligonucleotide Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Oligonucleotide Therapeutics Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Oligonucleotide Therapeutics Revenue (US$, Mn), 2022-2027
Table 17. Biogen Company Details
Table 18. Biogen Business Overview
Table 19. Biogen Oligonucleotide Therapeutics Product
Table 20. Biogen Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. Biogen Recent Developments
Table 22. Sarepta Therapeutics Company Details
Table 23. Sarepta Therapeutics Business Overview
Table 24. Sarepta Therapeutics Oligonucleotide Therapeutics Product
Table 25. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Sarepta Therapeutics Recent Developments
Table 27. Jazz Pharmaceuticals Company Details
Table 28. Jazz Pharmaceuticals Business Overview
Table 29. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
Table 30. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. Jazz Pharmaceuticals Recent Developments
Table 32. Bausch & Lomb Company Details
Table 33. Bausch & Lomb Business Overview
Table 34. Bausch & Lomb Oligonucleotide Therapeutics Product
Table 35. Bausch & Lomb Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. Bausch & Lomb Recent Developments
Table 37. Alnylam Pharmaceuticals Company Details
Table 38. Alnylam Pharmaceuticals Business Overview
Table 39. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product
Table 40. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Alnylam Pharmaceuticals Recent Developments
Table 42. Dynavax Technologies Company Details
Table 43. Dynavax Technologies Business Overview
Table 44. Dynavax Technologies Oligonucleotide Therapeutics Product
Table 45. Dynavax Technologies Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. Dynavax Technologies Recent Developments
Table 47. Kastle therapeutics Company Details
Table 48. Kastle therapeutics Business Overview
Table 49. Kastle therapeutics Oligonucleotide Therapeutics Product
Table 50. Kastle therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. Kastle therapeutics Recent Developments
Table 52. Akcea Therapeutics Company Details
Table 53. Akcea Therapeutics Business Overview
Table 54. Akcea Therapeutics Oligonucleotide Therapeutics Product
Table 55. Akcea Therapeutics Oligonucleotide Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Akcea Therapeutics Recent Developments
List of FiguresFigure 1. Oligonucleotide Therapeutics Segment by Type
Figure 2. Oligonucleotide Therapeutics Segment by Application
Figure 3. United States Oligonucleotide Therapeutics Market Overview: 2020
Figure 4. United States Oligonucleotide Therapeutics Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Oligonucleotide Therapeutics Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2020
Figure 7. By Type - United States Oligonucleotide Therapeutics Revenue Market Share, 2016-2027
Figure 8. By Application - United States Oligonucleotide Therapeutics Revenue Market Share, 2016-2027
Figure 9. Biogen Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Bausch & Lomb Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Dynavax Technologies Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Kastle therapeutics Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Akcea Therapeutics Oligonucleotide Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)